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CASE PRESENTATION
A 68-year-old man with no significant past medical
history was transferred to our hospital for evaluation of
newly diagnosed acute leukemia. His bone marrow
biopsy showed acute undifferentiated leukemia. He was
initiated on standard induction chemotherapy with
cytarabine and idarubicin. His hospital course was
complicated by neutropenic fever secondary to
Fusobacterium bacteremia. He was started on antibiotic
th erapy with intravenous cefepim e an d oral
metronidazole. Intravenous vancomycin was added in
the setting of recurrent intermittent fevers. On hospital
day 20, he developed minimal hemoptysis, pleuritic
chest pain, and recurrent fevers. A CT scan of the chest
showed a right upper lobe band-like opacity. Due to
concern for possible invasive aspergillosis, he was
started on oral voriconazole. Serum galactomannan
was negative. Given the patient’s thrombocytopenia,
tissue diagnosis was deferred. Repeat CT of the chest
two weeks later showed an interval increase in the
right upper lobe spiculated mass with surrounding
ground glass “halo” (Figure 1). A presumptive diagnosis
of pulmonary aspergillosis was made in the setting of
prolonged neutropenia, classic symptomatology, and
rapid growth of the mass suggestive of an infectious
process, as well as the halo sign on CT. He was
discharged on voriconazole with plans for repeat
imaging in several weeks and possible tissue diagnosis
at that time.

Figure 2: A second case of the halo sign, often seen in early pulmonary aspergillosis
and aiding in prompt diagnosis in the correct clinical setting.

DISCUSSION
Members of the fungal genus Aspergillus have been
implicated as the causal organisms in a spectrum of
distinctive pulmonary pathologies in humans, including
allergic bronchopulmonary aspergillosis (ABPA), chronic
pulmonary aspergillosis, and invasive aspergillosis. The
extent of infection is largely determined by differences in
the host immunity-microbe interaction. Invasive
aspergillosis primarily occurs in the setting of immune
compromise, most commonly with acute leukemia,
recent hematopoietic stem cell transplant, neutropenia,
solid organ transplant on immunosuppression, and
chronic granulomatous disease. Pulmonary symptoms
typically include dyspnea, cough, and fever unresponsive
to broad-spectrum antibiotics. Pleuritic chest pain and
hemoptysis can occur due to vascular invasion. If
uncontrolled, Aspergillus can spread hematogenously
and seed all organ systems.
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Figure 1: The halo sign, as seen in our patient, is a nodule surrounded by ground
glass representing angioinvasive pulmonary infection
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Diagnosis can be difficult since the only definitive tests
are biopsy with positive histopathology or positive
cultures from a normally sterile location. Since biopsy is
often not performed, infection must often be presumed
on the basis of clinical suspicion, respiratory culture data,
and biomarkers such as galactomannan. A positive
respiratory culture is not sufficient for diagnosis since
Aspergillus is a common colonizer. In addition, negative
cultures do not rule out infection. In immunocompromised or neutropenic hosts, fever may be the only
presenting symptom. Patients with persistent fevers
despite an appropriate course of empiric antibiotics
(10-14 days) should be assessed for potential fungal
infection. In patients for whom aspergillosis is suspected,
CT scan may help in identifying early invasive disease
and, as some studies suggest, lead to earlier initiation of

antifungal therapy and better overall outcomes. The
earliest findings on CT are pulmonary nodules and the
classic halo sign.
The halo sign is a nodule with surrounding ground glass
opacity. It is thought to represent a central area of
infarction and coagulative necrosis with surrounding
alveolar hemorrhage due to angioinvasion and local
pathogen spread. Although statistics vary between
reports, one of the largest cohorts included 235 patients
with proven or probable invasive disease, of which 94%
had a macronodule and 60.9% had a positive halo sign.
The halo sign is not pathognomonic for invasive
aspergillosis, as it has also been described with other
angioinvasive organisms including pulmonar y
Mucormycosis and Pseudomonas. However, Aspergillus
is the most common pathogen in those at risk for
invasive fungal infection. Aspergillosis may also present
as a bronchopneumonia, which may be indistinguishable
from other more common causes. Treatment consists
of a 6 to 12 week course of voriconazole.

This article serves to provide several examples of the halo
sign as seen in patients with acute leukemia and
neutropenic fever (Figures 1 and 2). Prompt identification
of this characteristic radiographic finding and initiation of
early treatment for invasive pulmonary aspergillosis is
important as mortality rates from untreated infection
range from 29-90% depending on patient characteristics.
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